Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data presented on high-dose weekly Abraxane
January 20th, 2005
American Pharmaceutical Partners, Inc., (APPX) announced positive results from a recent phase II clinical study indicating that weekly administration of Abraxane (nanoparticle albumin-bound paclitaxel) resulted in long-term disease control in patients with metastatic breast cancer whose disease had progressed while being treated with Taxol or Taxotere (patients who are taxane-refractory). In addition, American Bioscience, Inc., (ABI) presented two posters detailing the transport mechanisms of the paclitaxel albumin-bound nanoparticle protein. These findings were presented at the 27th Annual San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. ...
Source: Women's Health Weekly (2005-01-20)
|
